Research Update End-year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

During the first year that the project has been active, we have made progress toward our objectives. The project goals have not been modified.

Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy.

Continue reading “Research Update End-year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update Mid-year 4 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma

Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Recently, advances in the understanding of human lymphomas have focused on the area of epigenetics.

Continue reading “Research Update Mid-year 4 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma”

Research Update Mid- and End-yr 1 CHF 02643-A: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity

Initial studies on cytotoxicity by the research team show that CBD has cytotoxic activity on a variety of canine cancer cell lines at modest concentrations in the laboratory. These effects cause apoptosis, or programmed cell death, within a very short time frame, suggesting a discrete mechanism.

Continue reading “Research Update Mid- and End-yr 1 CHF 02643-A: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”

Research Update End-year 2 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

Hemangiosarcoma (HSA) accounts for the majority of canine malignant splenic tumors and occurs in many large dog breeds, including mixed breeds. A less common site of HSA localization is the heart (cardiac HSA). Risk factors for both cardiac and splenic HSA remain unclear, confounding development of preventative strategies. The investigators recently reported a high prevalence of species of the bacterial genus Bartonella in dogs with HSA from North Carolina, suggesting a potential role in the initiation and/or progression of this cancer.

Continue reading “Research Update End-year 2 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”